Fireside chat: Sector Focus – Life Sciences

Global activity in the biopharma segment is due to rebound in 2023 as companies saw valuations dwindle, meaning that companies are now incentivised to acquire ‘cheap’ targets. According to Mergermarket data, the life sciences sector accounted for 13% of deal volume in Spain and 14% in Portugal last year. Life sciences was the most active sector for financial sponsors in Portugal last year. This session will review: 

  • What is driving activity in the life sciences sector in Iberia?
  • Has activity rebounded in 2023 compared to 2022 due to ‘cheap’ targets?
  • How are global macro-economic factors affecting activity in the sector?
  • How are depressed public markets affecting the dealmaking pipeline in the sector?
  • Speakers keyboard_arrow_down
    Antonio Herce Principal - Life Sciences Inveready
    Raúl Martín-Ruiz Partner Ysios Capital Bio
    Rupert Cocke Senior Editor, Head of Iberian Coverage Mergermarket